The structure of optimal statin initiation policies for patients with Type 2 diabetes

IIE Transactions on Healthcare Systems Engineering

Volumn 1, Issue 1, 2011, Pages 49-65

  Kurt, Murat ^a   Denton, Brian T ^b   Schaefer, Andrew J ^a   Shah, Nilay D ^c   Smith, Steven A ^c  

^a University of Pittsburgh   (United States)

^b North Carolina State University   (United States)

^c Mayo Clinic   (United States)

Author keywords

control limit policy; diabetes; Markov decision processes

Indexed keywords

CHOLESTEROL; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID;

ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL (TOPIC); DECISION MAKING; HEALTH CARE POLICY; HUMAN; ISCHEMIC HEART DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RISK FACTOR; SENSITIVITY ANALYSIS;

EID: 84888344610     PISSN: 19488300     EISSN: 19488319     Source Type: Journal    
DOI: 10.1080/19488300.2010.550180     Document Type: Article

References (59)

1. Alagoz, O., Hsu, H., Schaefer, A. J. and Roberts, M. S. 2010. Markov decision processes: A tool for sequential decision making under uncertainty. Medical Decision Making, 30(4): 474-483.
2. Alagoz, O., Maillart, L. M., Schaefer, A. J. and Roberts, M. S. 2004. The optimal timing of living-donor liver transplantation. Management Science, 50(10): 1420-1430.
3. American Diabetes Association. 2008. Information and data accessed on May 1, 2009, http://www.diabetes.org
4. Anderson, K. A., Odel, P. M., Wilson, P. W. F. and Kannel, W. B. 1991. Cardiovascular disease risk profiles. American Heart Journal, 121(2): 293-298.
5. Barlow, R. E. and Proschan, F. 1965. Mathematical Theory of Reliability, New York: John Wiley & Sons.
6. Briel, M., Studer, M., Glass, T. R. and Bucher, H. C. 2004. Effects of statins on stroke prevention in patients with and without coronary heart disease: A meta-analysis of randomized controlled trials. American Journal of Medicine, 117(8): 596-606.
7. British Cardiac Society, British Hypertension Society, Diabetes UK, HEART UK, Primary Care Cardiovascular Society and The Stroke Association. 2005. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart, 91: 1-52.
8. rd National Health and Nutrition Examination Survey, 1988-1991. Hypertension, 25(3): 305-313.
9. Carrera, T., Bonamusa, L., Almirall, L. and Navarro, J. M. 1998. Should age and sex be taken into account in the determination of HbA1c reference range?. Diabetes Care, 21(12): 2193-2194.
10. Colhoun, H., Betteridge, D. J., Durrington, P. N., Hitman, G. A., Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V. and Fuller, J. H. 2004. Primary prevention of cardiovascular disease with atorvastatin in Type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial. Lancet, 364(9435): 685-696.
11. Collins, R., Armitage, J., Parish, S., Sleight, P. and Peto, R. 2002. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet, 360(9426): 7-22.
12. Collins, R., Armitage, J., Parish, S., Sleight, P. and Peto, R. 2003. MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebo-controlled trial. Lancet, 361(9374): 2005-2016.
13. Denton, B. T., Kurt, M., Shah, N. D., Bryant, S. C. and Smith, S. A. 2009. Optimizing the start time of statin therapy for patients with diabetes. Medical Decision Making, 29(3): 351-368.
14. Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A. and Air Force/Texas Coronary Atherosclerosis Prevention Study Group. 1998. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Journal of the American Medical Association, 279(20): 1615-1622.
15. Drummond, M. F., O'Brien, B., Stoddart, G. L. and Torrance, G. W. 1997. Methods for the Economic Evaluation of Health Care Programmes, Oxford, England: Oxford University Press.
16. Eddy, D. M. and Schlessinger, L. 2003a. Archimedes - a trial-validated model of diabetes. Diabetes Care, 26(11): 3093-3101.
17. Eddy, D. M. and Schlessinger, L. 2003b. Validation of the Archimedes diabetes model. Diabetes Care, 26(11): 3102-3110.
18. Fourth Joint Task Force of the European Society of Cardiology. 2007. European guidelines on cardiovascular disease prevention in clinical practice: Executive summary. European Heart Journal, 194(1): 1-45.
19. Garber, A. R., Olshen, R. A., Zhang, H. and Venatraman, E. S. 1994. Predicting high risk cholesterol levels. International Statistical Review, 62(2)
20. Gold, M. R., Patrick, D. L., Torrance, G. W., Fryback, D. G., Hadorn, D. C., Kamlet, M. S., Daniels, N. and Weinstein, M. C. 1996. "Identifying and valuing outcomes". In Cost-Effectiveness in Health and Medicine, Edited by: Gold, M. R., Siegel, J. E., Russell, L. B. and Weinstein, M. C. 82-134. New York: Oxford University Press.
21. Gold, M. R., Stevenson, D. and Fryback, D. G. 2002. HALYs and QALYs and DALYs, oh my: Similarities and differences in summary measures of population health. Annu. Rev. Public Health, 23: 115-134.
22. Hajjar, I. and Kotchen, T. A. 2003. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. Journal of the American Medical Association, 290(2): 199-206.
23. Honeycutt, A. A., Boyle, J. P., Broglio, K. R., Thompson, T. J., Hoerger, T. J., Geiss, L. S. and Venkat Narayan, K. M. 2003. A dynamic Markov model for forecasting diabetes prevalence in the United States through 2050. Health Care Management Science, 6(3): 155-164.
24. Kannel, W. B. 1996. Blood pressure as a cardiovascular risk factor. Journal of the American Medical Association, 275(20): 1571-1576.
25. Karp, I., Chen, S. F. and Pilote, L. 2007. Sex differences in the effectiveness of statins after myocardial infarction. Canadian Medical Association Journal, 176(3): 333-338.
26. Kilpatrick, E. S., Dominiczak, M. H. and Small, M. 1996. The effects of ageing on glycation and the interpretation of glycaemic control in Type 2 diabetes. QJM: An International Journal of Medicine, 89(4): 307-312.
27. Kothari, V., Stevens, R. J., Adler, A. I., Stratton, I. M., Manley, S. E., Neil, H. A. and Holman, R. R. 2002. UKPDS 60 - risk of stroke in Type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. Stroke, 33(7): 1776-1781.
28. Kreke, J. E., Bailey, M. D., Schaefer, A. J., Roberts, M. S. and Angus, D. C. 2008. Modeling hospital discharge policies for patients with pneumonia-related sepsis. IIE Transactions, 40(9): 861-869.
29. National Center for Health Statistics (NCHS). 2005. Mortality data from the National Vital Statistics System. Information and data accessed on November 1, 2009, http://www.cdc.gov/nchs/deaths.htm
30. National Cholesterol Education Program. 2001. Executive summary of the 3rd report of the NCEP expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Journal of the American Medical Association, 285(19): 2486-2497.
31. National Heart Foundation of Australia, and The Cardiac Society of Australia and New Zealand. 2001. Lipid management guidelines supplement. The Medical Journal of Australia, 175: s57-s88.
32. New Zealand Guidelines Group. 2003. The assessment and management of cardiovascular risk. Information and data accessed on May 1, 2009, http://www.nzgg.org.nz
33. Pasternak, R. C., Smith, S. C., Bairey-Merz, C. N. Jr., Grundy, S. M., Cleeman, J. I. and Lenfant, C. 2002. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Journal of the American College of Cardiology, 40(3): 567-572.
34. Phillips, P. S., Haas, R. H., Bannykh, S., Hathaway, N. L., Gray, S. and Kimura, B. J. 2002. Statin-associated myopathy with normal creatine kinase levels. Annals of Internal Medicine, 137(7): 581-585.
35. Pignone, M., Earnshaw, S., Tice, J. A. and Pletcher, M. J. 2006. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: A cost-utility analysis. Annals of Internal Medicine, 144(5): 326-336.
36. Pilote, L., Dasgupta, K., Guru, V., Humphries, K. H., McGrath, J., Norris, C., Rabi, D., Tremblay, J., Alamian, A., Barnett, T., Cox, J., Ghali, W. A., Grace, S., Hamet, P., Ho, T., Kirkland, S., Lambert, M., Libersan, D., O'Loughlin, J., Paradis, G., Petrovich, M. and Tagalakis, V. 2007. A comprehensive view of sex-specific issues related to cardiovascular disease. Canadian Medical Association Journal, 176(6): S1-44.
37. Snow, V., Aronson, M. D., Hornbake, E. R., Mottur-Pilson, C. and Weiss, K. B. 2004. Lipid control in the management of Type 2 diabetes mellitus: A clinical practice guideline from the American College of Physicians. Annals of Internal Medicine, 140(8): 644-649.
38. Stevens, R. J., Kothari, V., Adler, A. I., Stratton, I. M. and Holman, R. R. 2001. The UKPDS risk engine: A model for the risk of coronary heart disease in Type 2 diabetes (UKPDS 56). Clinical Science, 101(6): 671-679.
39. Timbie, J. W., Hayward, R. A. and Vijan, S. 2010. Variation in the net benefit of aggressive cardiovascular risk factor control across the US population of patients with diabetes mellitus. Archives of Internal Medicine, 170(12): 1037-1044.
40. Tsevat, J., Kuntz, K. M., Orav, E. J., Weinstein, M. C., Sacks, F. M. and Goldman, L. 2001. Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels. American Heart Journal, 141(5): 727-734.
41. Turner, R. C. 1998. The UK Prospective Diabetes Study - a review. Diabetes Care, 21: C35-C38.
42. UKPDS Group. 1998. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet, 352(6): 837-853.
43. Valdez-Flores, C. and Feldman, R. M. 1989. A survey of preventive maintenance models for stochasically deteriorating single-unit systems. Naval Research Logistics, 36(4): 419-446.
44. Vijan, S. and Hayward, R. A. 2004. Pharmacologic lipid-lowering therapy in Type 2 diabetes mellitus: Background paper for the American College of Physicians. Annals of Internal Medicine, 140(8): 650-658.
45. Walsh, J. M. E. and Pignone, M. 2004. Drug treatment of hyperlipidemia in women. Journal of the American Medical Association, 291(18): 2243-2252.
46. Wannamethee, S. G., Shaper, A. G. and Ebrahim, S. 2000. HDL-cholesterol, total cholesterol, and the risk of stroke in middle-aged British men. Stroke, 31(8): 1882-1888.
47. Denton, B. T., Kurt, M., Shah, N. D., Bryant, S. C. and Smith, S. A. 2009. Optimizing the start time of statin therapy for patients with diabetes. Medical Decision Making, 29(3): 351-368.
48. Gorman, C. A., Zimmerman, B. R., Smith, S. A., Dinneen, S. F., Knudsen, J. B., Holm, D., Jorgensen, B., Bjornsen, S., Planet, K., Hanson, P. and Rizza, R. A. 2000. DEMS - a second generation diabetes electronic management system. Computer Methods and Programs in Biomedicine, 62(2): 127-140.
49. Hebert, P. R., Gaziano, J. M., Chan, K. S. and Hennekens, C. H. 1997. Cholesterol lowering with statin drugs, risk of stroke, and total mortality - an overview of randomized trials. Journal of the American Medical Association, 278(4): 313-321.
50. Kothari, V., Stevens, R. J., Adler, A. I., Stratton, I. M., Manley, S. E., Neil, H. A. and Holman, R. R. 2002. UKPDS 60 - risk of stroke in Type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. Stroke, 33(7): 1776-1781.
51. Maron, D. J., Fazio, S. and Linton, M. F. 2000. Current perspectives on statins. Circulation, 101(2): 207-213.
52. National Center for Health Statistics (NCHS). 2009. Mortality data from the National Vital Statistics System, 2005. Information and data accessed on November 1, 2009, http://www.cdc.gov/nchs/deaths.htm
53. rd report of the NCEP expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Journal of the American Medical Association, 285(19): 2486-2497.
54. Puterman, M. L. 1994. Markov Decision Processes: Discrete Stochastic Dynamic Programming, New York: John Wiley & Sons.
55. Shechter, S. M. 2006. Optimal Scheduling of Highly Active Antiretroviral Therapies for HIV Patients, PhD thesis, University of Pittsburgh, USA
56. Snow, V., Aronson, M. D., Hornbake, E. R., Mottur-Pilson, C. and Weiss, K. B. 2004. Lipid control in the management of Type 2 diabetes mellitus: A clinical practice guideline from the American College of Physicians. Annals of Internal Medicine, 140(8): 644-649.
57. Stevens, R. J., Kothari, V., Adler, A. I., Stratton, I. M. and Holman, R. R. 2001. The UKPDS risk engine: A model for the risk of coronary heart disease in Type 2 diabetes (UKPDS 56). Clinical Science, 101(6): 671-679.
58. Vijan, S. and Hayward, R. A. 2004. Pharmacologic lipid-lowering therapy in Type 2 diabetes mellitus: Background paper for the American College of Physicians. Annals of Internal Medicine, 140(8): 650-658.
59. Warnick, G. R., Knopp, R. H., Fitzpatrick, V. and Branson, L. 1990. Estimating low-density lipoprotein cholesterol by the Friedewald equation is adequate for classifying patients on the basis of nationally recommended cutpoints. Clinical Chemistry, 36(1): 15-19.